Mera Pharmaceuticals Stock Net Income
| MRPI Stock | USD 0.0001 0.00 0.00% |
In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mera Pharmaceuticals, as well as the relationship between them.
Mera Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Mera Pharmaceuticals' valuation are provided below:Mera Pharmaceuticals does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Mera |
Mera Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Mera Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Mera Pharmaceuticals.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Mera Pharmaceuticals on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Mera Pharmaceuticals or generate 0.0% return on investment in Mera Pharmaceuticals over 90 days. Mera Pharmaceuticals, Inc. focuses on the development and commercialization of natural products from microalgae using it... More
Mera Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Mera Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Mera Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
Mera Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mera Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Mera Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Mera Pharmaceuticals historical prices to predict the future Mera Pharmaceuticals' volatility.Mera Pharmaceuticals Backtested Returns
We have found three technical indicators for Mera Pharmaceuticals, which you can use to evaluate the volatility of the firm. The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Mera Pharmaceuticals are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Mera Pharmaceuticals has perfect predictability. Overlapping area represents the amount of predictability between Mera Pharmaceuticals time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Mera Pharmaceuticals price movement. The serial correlation of 1.0 indicates that 100.0% of current Mera Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Mera Pharmaceuticals reported net income of (5,580). This is 100.0% lower than that of the Biotechnology sector and 100.01% lower than that of the Health Care industry. The net income for all United States stocks is 100.0% higher than that of the company.
Mera Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mera Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Mera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Mera Pharmaceuticals by comparing valuation metrics of similar companies.Mera Pharmaceuticals is currently under evaluation in net income category among its peers.
Mera Fundamentals
| Return On Asset | -1.74 | |||
| Current Valuation | 167.19 K | |||
| Shares Outstanding | 557.3 M | |||
| Price To Sales | 3.62 X | |||
| Revenue | 302.62 K | |||
| Gross Profit | 286.36 K | |||
| EBITDA | (192.75 K) | |||
| Net Income | (5.58 K) | |||
| Cash And Equivalents | 4.32 K | |||
| Total Debt | 299.14 K | |||
| Current Ratio | 0.06 X | |||
| Cash Flow From Operations | (71.84 K) | |||
| Beta | 3.16 | |||
| Market Capitalization | 222.92 K | |||
| Total Asset | 71 K | |||
| Retained Earnings | (8.89 M) | |||
| Working Capital | (881 K) | |||
| Current Asset | 54 K | |||
| Current Liabilities | 935 K |
About Mera Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mera Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mera Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VGIAX | Vanguard Growth And | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| ASML | ASML Holding NV |
Other Information on Investing in Mera Pink Sheet
Mera Pharmaceuticals financial ratios help investors to determine whether Mera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mera with respect to the benefits of owning Mera Pharmaceuticals security.